• Title/Summary/Keyword: Radiation medicine

Search Result 3,968, Processing Time 0.03 seconds

Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report

  • Joo, Ji Hyeon;Kim, Yeon Joo;Kim, Young Seok;Choi, Eun Kyung;Kim, Jong Hoon;Lee, Sang-Wook;Song, Si Yeol;Yoon, Sang Min;Kim, Su Ssan;Park, Jin-Hong;Jeong, Yuri;Ahn, Hanjong;Kim, Choung-Soo;Lee, Jae-Lyun;Ahn, Seung Do
    • Radiation Oncology Journal
    • /
    • v.31 no.4
    • /
    • pp.199-205
    • /
    • 2013
  • Purpose: To assess the clinical efficacy and toxicity of whole pelvic intensity-modulated radiotherapy (WP-IMRT) for high-risk prostate cancer. Materials and Methods: Patients with high-risk prostate cancer treated between 2008 and 2013 were reviewed. The study included patients who had undergone WP-IMRT with image guidance using electronic portal imaging devices and/or cone-beam computed tomography. The endorectal balloon was used in 93% of patients. Patients received either 46 Gy to the whole pelvis plus a boost of up to 76 Gy to the prostate in 2 Gy daily fractions, or 44 Gy to the whole pelvis plus a boost of up to 72.6 Gy to the prostate in 2.2 Gy fractions. Results: The study cohort included 70 patients, of whom 55 (78%) had a Gleason score of 8 to 10 and 50 (71%) had a prostate-specific antigen level > 20 ng/mL. The androgen deprivation therapy was combined in 62 patients. The biochemical failure-free survival rate was 86.7% at 2 years. Acute any grade gastrointestinal (GI) and genitourinary (GU) toxicity rates were 47% and 73%, respectively. The actuarial rate of late grade 2 or worse toxicity at 2 years was 12.9% for GI, and 5.7% for GU with no late grade 4 toxicity. Conclusion: WP-IMRT was well tolerated with no severe acute or late toxicities, resulting in at least similar biochemical control to that of the historic control group with a small field. The long-term efficacy and toxicity will be assessed in the future, and a prospective randomized trial is needed to verify these findings.

Concurrent Chemoradiotherapy versus Radiation Alone in Nasopharyngeal Carcinoma (비인강암에서 동시 항암방사선치료와 방사선치료 단독의 비교 연구)

  • Park Jin-Hong;Chang Hye-Sook;Kim Sung-Rae;Kim Sang-Yoon;Nam Soon-Yuhl;Cho Kyung-Ja;Kim Jong-Hoon;Ahn Seung-Do;Noh Young-Ju;Choi Eun-Kyung;Lee Sang-Wook
    • Korean Journal of Head & Neck Oncology
    • /
    • v.18 no.1
    • /
    • pp.30-35
    • /
    • 2002
  • Objective: To determine the effectiveness and toxicity of chemoradiation therapy in nasopharyngeal carcinoma by comparing with radiation therapy alone. Materials and Methods: Between October 1989 and July 2000, One hundred eleven patients with newly diagnosed and histologically proven nasopharyngeal carcinoma treated in Department of Radiation Oncology, Asan Medical Center were retrospectively reviewed. Forty-five patients were treated with radiation therapy alone (Group I) and 66 patients were treated with radiation therapy and concurrent cisplatin (Group II). Cisplatin was administered once a week, on the first day of each successive week of treatment, starting on day 1 of radiation therapy and given as a intravenous bolus at a dose of $20mg/m^2$ of body-surface area. Radiation therapy was given in doses of 1.8Gy, once a day, 5 days per week with 4MV or 6 MV photons. Initial field was received a total of 60Gy and a primary tumor and enlarged lymph nodes were boosted with an high dose intracavitory brachytherapy and 3D conformal therapy. Results: The complete response rate was 86.7% in Group I, and was 90.9% in Group II. The 5 year overall survival rate for Group I was 60% and for Group II was 45% (p=0.2520). The 5 year disease free survival rate was 52% versus 45%, respectively (p=0.7507). The median follow up was 44 months versus 34 months, respectively. Conclusion: Analysis of the III patients showed no significant difference in disease free survival and overall survival in two treatment group. This retrospective analysis did not demonstrate benefit with concurrent chemoradiation using cisplatin at a dose of $20mg/m^2$ of body-surface area in treatment result than radiation alone.

Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation

  • Byun, Hwa Kyung;Yoon, Hong In;Cho, Jaeho;Kim, Hyun Ju;Min, Yoo Hong;Lyu, Chuhl Joo;Cheong, June-Won;Kim, Jin Seok;Kim, Hyo Sun;Kim, Soo-Jeong;Yang, Andrew Jihoon;Lee, Byung Min;Lee, Won Hee;Lee, Joongyo;Ahn, Ki Jung;Suh, Chang-Ok
    • Radiation Oncology Journal
    • /
    • v.35 no.3
    • /
    • pp.257-267
    • /
    • 2017
  • Purpose: Pulmonary toxicities, including infectious pneumonia (IP) and idiopathic pneumonia syndrome (IPS), are serious side effects of total body irradiation (TBI) used for myeloablative conditioning. This study aimed to evaluate clinical factors associated with IP and IPS following TBI. Materials and Methods: Fifty-eight patients with hematologic malignancies who underwent TBI before allogeneic hematopoietic stem cell transplantation between 2005 and 2014 were reviewed. Most patients (91%) received 12 Gy in 1.5 Gy fractions twice a day. Pulmonary toxicities were diagnosed based on either radiographic evidence or reduced pulmonary function, and were subdivided into IP and IPS based on the presence or absence of concurrent infection. Results: Pulmonary toxicities developed in 36 patients (62%); 16 (28%) had IP and 20 (34%) had IPS. IP was significantly associated with increased treatment-related mortality (p = 0.028) and decreased survival (p = 0.039). Multivariate analysis revealed that the risk of developing IPS was significantly higher in patients who received stem cells from a matched unrelated donor than from a matched sibling donor (p = 0.021; hazard ratio [HR] = 12.67; 95% confidence interval [CI], 1.46-110.30). Combining other conditioning agents with cyclophosphamide produced a higher tendency to develop IP (p = 0.064; HR = 6.19; 95% CI, 0.90-42.56). Conclusion: IP and IPS involve different risk factors and distinct pathogeneses that should be considered when planning treatments before and after TBI.

Abdomen Immobilization with Air Injected Balloon Blanket

  • Suh, Ye-Lin;Yi, Byong-Yong;Ahn, Seung-Do;Lee, Sang-Wook;Kim, Jong-Hoon;Shin, Seung-Ai;Park, Eun-Kyung
    • Proceedings of the Korean Society of Medical Physics Conference
    • /
    • 2002.09a
    • /
    • pp.100-102
    • /
    • 2002
  • The demand for a better immobilization device has been increased in the radiation oncology field. Especially, it is essential to have a reliable and practical immobilization tool for the whole body radiosurgery and the IMRT (intensity modulated radiation therapy). A useful method to immobilize the abdomen for the external beam radiation treatment is developed. The air-injected balloon blanket (AIBB) was designed as an immobilization device. As the air was injected into it, it pressed down the patient's abdomen and fixed the patient. The AIBB played a role not only to grab the patients' motion, but also to increase the patients' setup reproducibility. Patients' movements due to the respiration were reduced and the reconstruction could be maximized. The experimental results revealed that the AIBB could be used for the clinic.

  • PDF

Radiotherapy of Para-Aortic Node Metastases in Carcinoma of the Uterine Cervix (자궁경부암에서 대동맥 임파절 전이의 치료)

  • Lee Jong Young;Suh Chang Ok;Seong Jin Sil;Kim Gwi Eon;John Juhn-Kyu
    • Radiation Oncology Journal
    • /
    • v.7 no.2
    • /
    • pp.259-267
    • /
    • 1989
  • Forty one patients with para-aortic node metastases from carcinoma of the uterine cervix treated with radiotherapy at Department of Radiation Oncology, Yonsei University, College of Medicine from January 1982 to December 1987 were retrospectively analyzed. Eleven patients were diagnosed at the time of diagnosis of carcinoma of the cervix (early diagnosis) and 30 patients were diagnosed during follow up period after definitive radiotherapy of primary site (late diagnosis). The most important factors affecting the survival in this study were time of diagnosis and dose of irradiation. Overall 5 year actuarial survival rate of 41 patients was $25.7\%$. Five year survival rate for early diagnosis was $60.3\%$, but late diagnosis was $16.9\%$. And survival rate for high dose (over 4000 cGy) radiation group and low dose radiation group were $42.2\%\;and\;8.9\%$ respectively The most leading cause of death was para-aortic node failure, so early diagnosis and maximum palliation with full dose radiotherapy (over 4000 cGy) is necessary to improve the survival and the quality of life.

  • PDF

Initial Experience of Patient-Specific QA for Wobbling and Line-Scanning Proton Therapy at Samsung Medical Center

  • Jo, Kwanghyun;Ahn, Sung Hwan;Chung, Kwangzoo;Cho, Sungkoo;Shin, Eun Hyuk;Park, Seyjoon;Hong, Chae-Seon;Kim, Dae-Hyun;Lee, Boram;Lee, Woojin;Choi, Doo Ho;Lim, Do Hoon;Pyo, Hong Ryull;Han, Youngyih
    • Progress in Medical Physics
    • /
    • v.30 no.1
    • /
    • pp.14-21
    • /
    • 2019
  • Purpose: To report the initial experience of patient-specific quality assurance (pQA) for the wobbling and line-scanning proton therapy at Samsung Medical Center. Materials and Methods: The pQA results of 89 wobbling treatments with 227 fields and 44 line-scanning treatments with 118 fields were analyzed from December 2015 to June 2016. For the wobbling method, proton range and spread-out Bragg peak (SOBP) width were verified. For the line-scanning method, output and two-dimensional dose distribution at multiple depths were verified by gamma analysis with 3%/3 mm criterion. Results: The average range difference was -0.44 mm with a standard deviation (SD) of 1.64 mm and 0.1 mm with an SD of 0.53 mm for the small and middle wobbling radii, respectively. For the line-scanning method, the output difference was within ${\pm}3%$. The gamma passing rates were over 95% with 3%/3 mm criterion for all depths. Conclusions: For the wobbling method, proton range and SOBP width were within the tolerance levels. For the line-scanning method, the output and two-dimensional dose distribution showed excellent agreement with the treatment plans.